Jiangsu Hengrui Medicine
600276.SS
#507
Rank
NZ$69.48 B
Marketcap
$10.89
Share price
0.07%
Change (1 day)
7.19%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): $0.15

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is $0.16. In 2022 the company made an earnings per share (EPS) of $0.16 a decrease over its 2021 EPS that were of $0.19.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.15-5.93%
2022$0.16-17.1%
2021$0.19-24.44%
2020$0.2520.3%
2019$0.2125.58%
2018$0.1727.55%
2017$0.1321.64%
2016$0.1113.57%
2015$0.0952639.86%
2014$0.0681121.33%
2013$0.0561317.7%
2012$0.0476925.56%
2011$0.0379826.22%
2010$0.0300910.3%
2009$0.0272857.92%
2008$0.0172811.06%
2007$0.0155685.81%
2006$0.00837287.94%
2005$0.00445433.97%
2004$0.00332529.78%
2003$0.00256219.78%
2002$0.002139